TLDR: Arena BioWorks has launched as a biomedical research institute that will create for-profit biotech companies to develop lifesaving therapeutics. The company, which is supported by co-founders Harvard University scientist Stuart Schreiber, former Bain Capital Co-Chair Steve Paglicua and Tom Cahill of venture capital firm Newpath Partners, will use private funding to quickly translate insights into discovery. Use of drug discovery platforms will also be supported through preclinical studies and beyond.
Accelerating Insight to Therapeutics: Introducing Arena BioWorks’ Biomedical Breakthroughs

Latest from Blog

VCFA Group Closes $1225M Venture Partners VII Fund
TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in

VCFA Group’s Venture Partners VII Fund Raises $1225 Million
TLDR: VCFA Group closed its latest fund, VCFA Venture Partners VII, with $122.5 million in commitments. The fund focuses on smaller and more complex purchases of later-stage venture capital and growth equity

Revolutionizing Payments: $20M Raised for Stablecoin Network Development
TLDR: 1Money has raised over $20 million in seed funding to develop a stablecoin payments network. The network aims to offer instant transaction confirmation, low-cost fees, multicurrency support, compliance mechanisms, and scalability.

Top AI Trends and Startups Shaping 2025 and Beyond
“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI

Sand Hill Road: Steve Vassallo’s Early Investment Edge at Foundation Capital
“`html TLDR: Steve Vassallo, a general partner at Foundation Capital, focuses on early-stage investments, often being the first institutional investor for startups. He emphasizes the importance of owning a significant stake in